Glucagon I

  • Pierre J. Lefèbvre

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 66 / 1)

Table of contents

  1. Front Matter
    Pages I-XXVIII
  2. Chemistry and Physicochemistry of Glucagon

    1. Front Matter
      Pages ins1-ins1
    2. W. W. Bromer
      Pages 1-22
    3. R. B. Merrifield, S. Mojsov
      Pages 23-35
    4. T. L. Blundell
      Pages 37-56
  3. Morphology of the A-cell of Islets of Langerhans, Biosynthesis of Glucagon and Related Peptides

    1. Front Matter
      Pages ins2-ins2
    2. L. Orci, C. Bordi, R. H. Unger, A. Perrelet
      Pages 57-79
    3. S. Falkmer, S. Van Noorden
      Pages 81-119
    4. C. Hellerström
      Pages 121-138
    5. A. J. Moody, L. Thim
      Pages 139-174
  4. Production and Assay of Glucagon

    1. Front Matter
      Pages ins3-ins3
    2. M. Pingel, B. Skelbaek-Pedersen, J. Brange
      Pages 175-188
    3. L. G. Heding
      Pages 189-201
    4. J. W. Ensinck
      Pages 203-221
    5. J. J. Holst
      Pages 245-261
  5. Actions of Glucagon

    1. Front Matter
      Pages ins4-ins4
    2. W. Stalmans
      Pages 291-314
    3. T. H. Claus, C. R. Park, S. J. Pilkis
      Pages 315-360

About this book

Introduction

The Editorial Board of the Handbook of Experimental Pharmacology apparently did not hurry in suggesting production of a volume on glucagon since the present opus is number sixty-six in the series. This fact is even more striking if we consider that 34 volumes published over about eight years will separate the books on glucagon from those on insulin on library shelves, whereas only a few microns separate the cells manufacturing these two polypeptides within the islets of Langerhans in the pancreas! Numerous factors have probably caused this dicrimination; four of them are: First, insulin deficiency or resistance is the cause of one of the most serious and distressing diseases, diabetes mellitus, which affects millions of people, whereas glucagon deficiency is apparently an extremely rare disorder, for which detailed reports are published of individual cases whenever they occur. Second, since its discovery in 1921 by BANTING and BEST, insulin has been irreplaceable for the treatment of the most severe forms of diabetes, whereas, in contrast, glucagon was until recently considered a relatively minor therapeutic agent. Third, whereas insulin is a compound which has been well characterized since the pioneering work of SANGER and its biosynthesis clearly identified by STEINER and his co-workers, glucagon, also well characterized chemically, has suffered from its parenthood with the so-called "glucagon-like immunoreactive substances", an incompletely defined series of immunologically related polypeptides present in the gut, the pancreas and some other parts of the body.

Keywords

Drogen Glucagon Hormone Hypophyse Insulin Prostaglandin Sepsis antibody antigen chemistry chromatography metabolism nutrition pharmacology resistance

Editors and affiliations

  • Pierre J. Lefèbvre
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
  1. 1.University of LiègeBelgium
  2. 2.University of Brussels (V.U.B.)Belgium
  3. 3.Royal Academy of Medicine of BelgiumBelgium
  4. 4.Medical PoliclinicsUniversity of LiègeBelgium
  5. 5.Division of DiabetesUniversity of LiègeBelgium
  6. 6.Institut de MèdecineHôpital de BavièreLiègeBelgium

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-68866-9
  • Copyright Information Springer-Verlag Berlin Heidelberg 1983
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-68868-3
  • Online ISBN 978-3-642-68866-9
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325
  • About this book
Industry Sectors
Chemical Manufacturing
Biotechnology
Consumer Packaged Goods
Pharma